Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: Studies of direct comparison are useful

2018-01-04 Four dossier assessments in 2017 involving comparisons between immunotherapies and chemotherapies for the same indication. Yet, a comparison of immunotherapies among each other is missing.

read more Link to \Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: Studies of direct comparison are useful\""

Early benefit assessments: IQWiG completed 220th dossier assessment by the turn of the year

2018-01-18 A host of dossiers assessed by IQWiG to date have addressed oncology drugs. Despite their significance, other diseases, e.g. Alzheimer dementia, are underrepresented.

read more Link to \Early benefit assessments: IQWiG completed 220th dossier assessment by the turn of the year\""

Finding RCTs of new drugs: Searches in trial registries require specific adaptations

2018-01-05 IQWiG authors report on the availability of randomized controlled trials (RCTs) of newly approved drugs in trial registries as well as on specific search strategies.

read more Link to \Finding RCTs of new drugs: Searches in trial registries require specific adaptations\""

Biomarker tests in early breast cancer: IQWiG criticizes interpretation of MINDACT data in an updated US guideline

2017-12-20 In their updated guideline, US oncologists recently recommended the MammaPrint test. Researchers from IQWiG have reacted in a letter to the editor in the Journal of Clinical Oncology.

read more Link to \Biomarker tests in early breast cancer: IQWiG criticizes interpretation of MINDACT data in an updated US guideline\""

Nivolumab in squamous cell carcinoma of the head and neck: added benefit for specific patients

2017-09-01 There is an indication of considerable added benefit in progression up to six months after platinum-based therapy. An added benefit is not proven for progression occurring later.

read more Link to \Nivolumab in squamous cell carcinoma of the head and neck: added benefit for specific patients\""

MRI-guided high-intensity focused ultrasound therapy for uterine fibroids has potential

2017-03-13 IQWiG has attributed a potential for a benefit to a new treatment method according to §137e SGB V. A testing study has been initiated. Numerous other assessments had no consequences.

read more Link to \MRI-guided high-intensity focused ultrasound therapy for uterine fibroids has potential\""

Bronchial carcinoma: added benefit of crizotinib not proven

2017-01-02 The dossier contains no data or no suitable data on ROS1-positive, advanced non-small cell lung cancer. Results on ALK-positive tumours are not applicable.

read more Link to \Bronchial carcinoma: added benefit of crizotinib not proven\""

Corneal collagen cross-linking for keratoconus: now data provide hint of benefit

2016-11-15 Additional data from an Australian study now show an advantage over purely symptomatic treatment. However, overall the evidence is still insufficient.

read more Link to \Corneal collagen cross-linking for keratoconus: now data provide hint of benefit\""

Acute leukaemia: The benefit of certain types of stem cell transplantation is currently not proven

2007-06-04 In the past few decades, stem cell transplantation has become a commonly used alternative to chemotherapy in patients with acute leukaemia. However, in some groups of patients, the scientific evaluati…

read more Link to \Acute leukaemia: The benefit of certain types of stem cell transplantation is currently not proven\""

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

There are no actual comments.


Calls for tenders advertised

Calls for tenders advertised

In general, calls for tenders are published in German. Interested parties can check current calls for tenders on the German website.


Easily understandable information for patients and the general community

Cabozantinib (Cabometyx) for the treatment of advanced renal cell cancer

The drug cabozantinib (trade name: Cabometyx) has been approved in Germany since September 2016 for the treatment of advanced renal cell cancer.   read more (Link to \Cabozantinib (Cabometyx) for the treatment of advanced renal cell cancer\"" ‚Äì opens in a new window)


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close